MedPath

An Observational Study of Epoetin Beta [Neorecormon] to Evaluate the Quality of Life in Patients on Dialysis With Chronic Renal Anemia

Completed
Conditions
Anemia
Registration Number
NCT01105494
Lead Sponsor
Hoffmann-La Roche
Brief Summary

This multicenter, prospective, observational study will evaluate the quality of life and the factors that influence the quality of life of epoetin beta \[Neorecormon\] in patients with renal chronic anemia, who are on dialysis. For each eligible patient data will be collected for 6 months. Target sample size is 5000-7000 patients.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
6000
Inclusion Criteria
  • Adult patients >/=18 years of age
  • Dialysis patients with chronic renal anemia
  • Written informed consent
Read More
Exclusion Criteria
  • Red blood cell transfusion in the previous 2 months
  • Severe neuropsychological disorder
  • Diabetic patients with serious complications

This trial is being conducted in Morocco.

Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Quality of life assessment: Kidney Disease Quality of Life QuestionnaireThroughout study: 6 months
Secondary Outcome Measures
NameTimeMethod
Evaluation of factors (demographic and social characteristics, dialysis method) influencing the quality of lifeThroughout study: 6 months
© Copyright 2025. All Rights Reserved by MedPath